Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report)'s share price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $0.97 and traded as high as $1.07. Clearside Biomedical shares last traded at $1.07, with a volume of 112,624 shares changing hands.
Analyst Upgrades and Downgrades
Several equities analysts have commented on CLSD shares. Chardan Capital reissued a "buy" rating and set a $6.00 target price on shares of Clearside Biomedical in a research note on Friday, November 15th. HC Wainwright reissued a "buy" rating and set a $6.00 target price on shares of Clearside Biomedical in a research note on Thursday, November 14th. Needham & Company LLC reissued a "buy" rating and set a $6.00 target price on shares of Clearside Biomedical in a research note on Wednesday, November 13th. Finally, StockNews.com raised shares of Clearside Biomedical from a "sell" rating to a "hold" rating in a research note on Thursday, December 12th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Clearside Biomedical currently has an average rating of "Moderate Buy" and an average target price of $5.33.
Check Out Our Latest Stock Analysis on CLSD
Clearside Biomedical Stock Performance
The company's 50 day moving average price is $0.97 and its 200-day moving average price is $1.07. The company has a market cap of $78.87 million, a price-to-earnings ratio of -2.31 and a beta of 2.22.
Hedge Funds Weigh In On Clearside Biomedical
Several hedge funds have recently made changes to their positions in CLSD. Johnson & Johnson purchased a new position in shares of Clearside Biomedical in the third quarter worth approximately $105,000. Geode Capital Management LLC increased its position in shares of Clearside Biomedical by 8.8% in the third quarter. Geode Capital Management LLC now owns 731,386 shares of the company's stock worth $929,000 after acquiring an additional 59,089 shares in the last quarter. Northern Trust Corp increased its position in shares of Clearside Biomedical by 24.0% in the fourth quarter. Northern Trust Corp now owns 165,499 shares of the company's stock worth $157,000 after acquiring an additional 32,048 shares in the last quarter. Finally, Investor s Fiduciary Advisor Network LLC purchased a new position in shares of Clearside Biomedical in the fourth quarter worth approximately $32,000. Institutional investors and hedge funds own 18.75% of the company's stock.
Clearside Biomedical Company Profile
(
Get Free Report)
Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.
Read More
Before you consider Clearside Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clearside Biomedical wasn't on the list.
While Clearside Biomedical currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
